[go: up one dir, main page]

CA2383026A1 - Traitement combine au moyen de il-1ra et de composes de diarylsulfonyluree - Google Patents

Traitement combine au moyen de il-1ra et de composes de diarylsulfonyluree Download PDF

Info

Publication number
CA2383026A1
CA2383026A1 CA002383026A CA2383026A CA2383026A1 CA 2383026 A1 CA2383026 A1 CA 2383026A1 CA 002383026 A CA002383026 A CA 002383026A CA 2383026 A CA2383026 A CA 2383026A CA 2383026 A1 CA2383026 A1 CA 2383026A1
Authority
CA
Canada
Prior art keywords
alkyl
urea
hydroxy
diisopropyl
sulfonyl
Prior art date
Legal status (The legal status is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the status listed.)
Abandoned
Application number
CA002383026A
Other languages
English (en)
Inventor
Bruce Henry Littman
Thasia Louise Goodwin Woodworth
Mark Anthony Dombroski
Current Assignee (The listed assignees may be inaccurate. Google has not performed a legal analysis and makes no representation or warranty as to the accuracy of the list.)
Pfizer Products Inc
Original Assignee
Individual
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Application filed by Individual filed Critical Individual
Publication of CA2383026A1 publication Critical patent/CA2383026A1/fr
Abandoned legal-status Critical Current

Links

Classifications

    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K38/00—Medicinal preparations containing peptides
    • A61K38/16—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof
    • A61K38/17—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof from animals; from humans
    • A61K38/19—Cytokines; Lymphokines; Interferons
    • A61K38/20—Interleukins [IL]
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A61K31/33—Heterocyclic compounds
    • A61K31/395—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins
    • A61K31/55—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having seven-membered rings, e.g. azelastine, pentylenetetrazole
    • A61K31/551—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having seven-membered rings, e.g. azelastine, pentylenetetrazole having two nitrogen atoms, e.g. dilazep
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A61K31/64—Sulfonylureas, e.g. glibenclamide, tolbutamide, chlorpropamide
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K45/00—Medicinal preparations containing active ingredients not provided for in groups A61K31/00 - A61K41/00
    • A61K45/06—Mixtures of active ingredients without chemical characterisation, e.g. antiphlogistics and cardiaca
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P19/00—Drugs for skeletal disorders
    • A61P19/02—Drugs for skeletal disorders for joint disorders, e.g. arthritis, arthrosis
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P29/00—Non-central analgesic, antipyretic or antiinflammatory agents, e.g. antirheumatic agents; Non-steroidal antiinflammatory drugs [NSAID]
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P43/00—Drugs for specific purposes, not provided for in groups A61P1/00-A61P41/00

Landscapes

  • Health & Medical Sciences (AREA)
  • Life Sciences & Earth Sciences (AREA)
  • General Health & Medical Sciences (AREA)
  • Pharmacology & Pharmacy (AREA)
  • Veterinary Medicine (AREA)
  • Chemical & Material Sciences (AREA)
  • Medicinal Chemistry (AREA)
  • Public Health (AREA)
  • Animal Behavior & Ethology (AREA)
  • Epidemiology (AREA)
  • Bioinformatics & Cheminformatics (AREA)
  • Organic Chemistry (AREA)
  • Engineering & Computer Science (AREA)
  • Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
  • General Chemical & Material Sciences (AREA)
  • Chemical Kinetics & Catalysis (AREA)
  • Rheumatology (AREA)
  • Immunology (AREA)
  • Proteomics, Peptides & Aminoacids (AREA)
  • Physical Education & Sports Medicine (AREA)
  • Orthopedic Medicine & Surgery (AREA)
  • Zoology (AREA)
  • Gastroenterology & Hepatology (AREA)
  • Pain & Pain Management (AREA)
  • Pharmaceuticals Containing Other Organic And Inorganic Compounds (AREA)
  • Medicines That Contain Protein Lipid Enzymes And Other Medicines (AREA)
  • Acyclic And Carbocyclic Compounds In Medicinal Compositions (AREA)

Abstract

L'invention concerne des procédés et des compositions servant à traiter et à prévenir des maladies dans lesquelles interleukine 1 (IL-1) joue un rôle. Ces procédés et ces compositions mettent en application un polypeptide antagoniste (IL-1ra) du récepteur d'interleukine 1 ou une de ses variantes en combinaison avec un agent non stéroïde inhibant le traitement et la libération d'IL-1.
CA002383026A 1999-09-14 2000-08-28 Traitement combine au moyen de il-1ra et de composes de diarylsulfonyluree Abandoned CA2383026A1 (fr)

Applications Claiming Priority (3)

Application Number Priority Date Filing Date Title
US15401099P 1999-09-14 1999-09-14
US60/154,010 1999-09-14
PCT/IB2000/001192 WO2001019390A1 (fr) 1999-09-14 2000-08-28 Traitement combine au moyen de il-1ra et de composes de diarylsulfonyluree

Publications (1)

Publication Number Publication Date
CA2383026A1 true CA2383026A1 (fr) 2001-03-22

Family

ID=22549650

Family Applications (1)

Application Number Title Priority Date Filing Date
CA002383026A Abandoned CA2383026A1 (fr) 1999-09-14 2000-08-28 Traitement combine au moyen de il-1ra et de composes de diarylsulfonyluree

Country Status (13)

Country Link
EP (1) EP1214087A1 (fr)
JP (1) JP2003509378A (fr)
AR (1) AR033650A1 (fr)
AU (1) AU6464400A (fr)
BR (1) BR0014003A (fr)
CA (1) CA2383026A1 (fr)
CO (1) CO5190701A1 (fr)
EC (1) ECSP003652A (fr)
GT (1) GT200000155A (fr)
PA (1) PA8502901A1 (fr)
PE (1) PE20010685A1 (fr)
TN (1) TNSN00183A1 (fr)
WO (1) WO2001019390A1 (fr)

Families Citing this family (34)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
JP2007531738A (ja) 2004-04-02 2007-11-08 アムジエン・インコーポレーテツド ＩＬ−１ｒａの凝集を低下させる方法
WO2008129288A2 (fr) * 2007-04-19 2008-10-30 Boehringer Ingelheim International Gmbh Disulfonamides utiles dans le traitement de l'inflammation
AU2016222278B2 (en) * 2015-02-16 2020-07-09 The Provost, Fellows, Foundation Scholars, And The Other Members Of Board, Of The College Of The Holy And Undivided Trinity Of Queen Elizabeth Near Dublin Sulfonylureas and related compounds and use of same
JP2019512009A (ja) 2016-02-16 2019-05-09 ザ・ユニバーシティ・オブ・クイーンズランド スルホニルウレアおよび関連化合物ならびにこれらの利用
ES2855732T3 (es) * 2016-04-18 2021-09-24 Novartis Ag Compuestos y composiciones para tratar afecciones asociadas con la actividad de NLRP
EP3571187B1 (fr) 2017-01-23 2023-11-22 Genentech, Inc. Composés chimiques comme inhibiteurs de l'activité interleukine-1
BR112019024831A2 (pt) 2017-05-24 2020-06-09 The University Of Queensland composto, sal, solvato ou pró-droga, composição farmacêutica, método de tratamento ou prevenção de uma doença, método para inibir o nlrp3
EP3634951B8 (fr) 2017-06-09 2024-08-21 Zydus Lifesciences Limited Nouveaux composés de sulfoximine substitués
LT3661925T (lt) 2017-07-07 2022-03-10 Inflazome Limited Naujieji sulfonamido karboksamido junginiai
EP3649112A1 (fr) 2017-07-07 2020-05-13 Inflazome Limited Sulfonylurées et sulfonylthiourées en tant qu'inhibiteurs de nlrp3
SI3658539T1 (sl) 2017-07-24 2024-06-28 Novartis Ag Spojine in sestavki za zdravljenje stanj, povezanih z delovanjem nlrp
US11926600B2 (en) 2017-08-15 2024-03-12 Inflazome Limited Sulfonylureas and sulfonylthioureas as NLRP3 inhibitors
BR112020002906A2 (pt) 2017-08-15 2020-08-04 Inflazome Limited novos compostos de sulfonamida-carboxamida
CA3071150A1 (fr) * 2017-08-15 2019-02-21 Inflazome Limited Sulfonylurees et sulfonylthiourees en tant qu'inhibiteurs de nlrp3
EP3668840A1 (fr) 2017-08-15 2020-06-24 Inflazome Limited Nouveaux composés de sulfonamide carboxamide
TW201910317A (zh) 2017-08-15 2019-03-16 愛爾蘭商英弗雷佐姆有限公司 新穎化合物
WO2019043610A1 (fr) 2017-08-31 2019-03-07 Cadila Healthcare Limited Nouveaux dérivés de sulfonylurées substitués
WO2019068772A1 (fr) 2017-10-03 2019-04-11 Inflazome Limited Nouveaux composés
WO2019092171A1 (fr) 2017-11-09 2019-05-16 Inflazome Limited Nouveaux composés de sulfonamide carboxamide
RU2020115098A (ru) 2017-11-09 2021-12-10 Инфлазоум Лимитед Соединения новых сульфонамидкарбоксамидов
EP3759102A1 (fr) 2018-03-02 2021-01-06 Inflazome Limited Nouveaux composés
US12030879B2 (en) 2018-03-02 2024-07-09 Inflazome Limited Sulfonyl acetamides as NLRP3 inhibitors
WO2019166628A1 (fr) 2018-03-02 2019-09-06 Inflazome Limited Nouveaux composés
EP3759077A1 (fr) 2018-03-02 2021-01-06 Inflazome Limited Nouveaux composés
US12168653B2 (en) 2018-03-02 2024-12-17 Inflazome Limited Sulfonamide derivates as NLRP3 inhibitors
WO2019166632A1 (fr) 2018-03-02 2019-09-06 Inflazome Limited Nouveaux composés
GB201806578D0 (en) * 2018-04-23 2018-06-06 Inflazome Ltd Novel compound
WO2020010143A1 (fr) 2018-07-03 2020-01-09 Novartis Inflammasome Research, Inc. Modulateurs de nlrp
KR20210034596A (ko) 2018-07-20 2021-03-30 에프. 호프만-라 로슈 아게 인터류킨-1 활성의 저해제로서 술폰이미드아미드 화합물
PE20211049A1 (es) 2018-07-20 2021-06-04 Hoffmann La Roche Compuestos de sulfonilurea como inhibidores de la actividad de interleucina 1
US12187702B2 (en) 2018-08-15 2025-01-07 Inflazome Limited Sulfonamideurea compounds
JP2022505525A (ja) * 2018-10-24 2022-01-14 ノバルティス アーゲー Ｎｌｒｐ活性に関連する状態を治療するための化合物及び組成物
CN120208846A (zh) 2019-01-14 2025-06-27 载度思生命科学有限公司 经取代的磺酰脲类衍生物
EP4157860A4 (fr) * 2020-05-25 2024-03-06 Beijing Vdjbio Co., Ltd. Antagoniste du récepteur de l'interleukine-1 et protéine de fusion le contenant

Family Cites Families (4)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
US5874424A (en) * 1995-12-20 1999-02-23 Vertex Pharmaceuticals Incorporated Inhibitors of interleukin-1β converting enzyme
EP0964849B1 (fr) * 1997-01-29 2003-06-04 Pfizer Inc. Derives de sulfonyluree et leur application en matiere de regulation de l'activite de l'interleukine-1
US6015790A (en) * 1997-10-06 2000-01-18 Basf Aktiengesellschaft Methods and compositions for treating rheumatoid arthritis
EP0987552A3 (fr) * 1998-08-31 2000-06-07 Pfizer Products Inc. Protéines de liaison pour diarylsulfonylurée

Also Published As

Publication number Publication date
CO5190701A1 (es) 2002-08-29
TNSN00183A1 (fr) 2005-11-10
JP2003509378A (ja) 2003-03-11
GT200000155A (es) 2002-03-08
BR0014003A (pt) 2002-05-21
AU6464400A (en) 2001-04-17
PA8502901A1 (es) 2002-02-21
AR033650A1 (es) 2004-01-07
WO2001019390A1 (fr) 2001-03-22
PE20010685A1 (es) 2001-07-03
EP1214087A1 (fr) 2002-06-19
ECSP003652A (es) 2002-04-23

Similar Documents

Publication Publication Date Title
CA2383026A1 (fr) Traitement combine au moyen de il-1ra et de composes de diarylsulfonyluree
CA2279186C (fr) Derives de sulfonyluree et leur application en matiere de regulation de l'activite de l'interleukine-1
US20030143230A1 (en) Combination of an IL-1/18 inhibitor with a TNF inhibitor for the treatment of inflammation
JP2005512522A5 (fr)
WO2008128038A2 (fr) Procédés et compositions permettant de traiter les dysfonctionnements cardiaques
KR20230018485A (ko) 폐에 대한 기계적 손상에 의해 촉진된 폐 섬유증 상태의 치료에 사용하기 위한 뉴로키닌 (nk)-1 수용체 길항제
JP7127988B2 (ja) 新規な組成物ならびに慢性閉塞性肺疾患を処置および／または予防する方法
JP2005519927A (ja) 多嚢胞性卵巣症候群の処置における、シルデナフィル如きｐｄｅ５インヒビターの使用
EP1270554A1 (fr) Dérivés de sulfonylurée et leur emploi dans le contrôle de l'activité de l'interleukine-1
US20150072995A1 (en) Treatment of male sexual dysfunction
EP2945932B1 (fr) Composés ayant un effet sur plusieurs récepteurs des prostaglandines et produisant une réponse anti-inflammatoire générale
US7423009B2 (en) Method for treatment of kidney diseases
JP2000086533A (ja) 新規なアレルギー治療剤
JP2004517046A (ja) 医薬
ZA200405208B (en) Treatment of male sexual dysfunction
MXPA99007030A (en) Sulfonyl urea derivatives and their use in the control of interleukin-1 activity
HK1073109B (en) Pharmaceutical composition for treatment of male sexual dysfunction
WO2004031777A1 (fr) Utilisation de gst-omega-2 en tant que cible therapeutique

Legal Events

Date Code Title Description
EEER Examination request
FZDE Dead